Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–92.

CAS  PubMed  Article  Google Scholar 

Liaw YF. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. Nat Rev Gastroenterol Hepatol. 2019;16:631–41.

PubMed  Article  Google Scholar 

Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.

CAS  PubMed  Article  Google Scholar 

Lampertico P, Agarwal K, Berg T, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.

Article  Google Scholar 

Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.

PubMed  Article  Google Scholar 

Clermont RJ, Chalmers TC. The transaminase tests in liver disease. Medicine (Baltimore). 1967;46:197–207.

CAS  Article  Google Scholar 

Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10.

CAS  PubMed  Article  Google Scholar 

Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83.

PubMed  Article  Google Scholar 

Neuschwander-Tetri BA, Unalp A, Creer MH. Nonalcoholic steatohepatitis clinical research network. The upper limits of normal for serum ALT levels reported by clinical laboratories depend on local reference populations. Arch Intern Med. 2004. https://doi.org/10.1001/archinternmed.2007.131.

Article  PubMed Central  Google Scholar 

Dutta A, Saha C, Johnson CS, Chalasani N. Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology. 2009;50:1957–62.

CAS  PubMed  Article  Google Scholar 

Panteghini M, Adeli K, Ceriotti F, Sandberg S, Horvath AR. American liver guidelines and cutoffs for “Normal” ALT: a potential for overdiagnosis. Clin Chem. 2017;63:1196–8.

CAS  PubMed  Article  Google Scholar 

Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007;46:395–401.

PubMed  Article  Google Scholar 

Manno M, Cammà C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology. 2004;127:756–63.

PubMed  Article  Google Scholar 

Tai DI, Lin SM, Sheen IS, et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology. 2009;49:1859–67.

CAS  PubMed  Article  Google Scholar 

Brahmania M, Lombardero M, Hansen BE, et al. Association between severe serum alanine aminotransferase flares and hepatitis B e antigen seroconversion and HBV DNA decrease in untreated patients with chronic HBV infection. Clin Gastroenterol Hepatol. 2019;17:2541–51.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Liem KS, Fung S, Wong DK, et al. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (toronto stop study). Gut. 2019;68:2206–13.

CAS  PubMed  Article  Google Scholar 

Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course and management. J Hepatol. 2014;61:1407–17.

PubMed  Article  Google Scholar 

Buti M, Gane E, Seto WK, Chan HL, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, Phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196–206.

PubMed  Article  Google Scholar 

Chu CM, Karayiannis P, Fowler MJF, Thomas HC, et al. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology. 1985;5:431–4.

CAS  PubMed  Article  Google Scholar 

Brunetto MR, Giarin MM, Oliveri F, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A. 1991;88:4186–90.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kennedy PTF, Sandalova E, Jo J, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology. 2012;143:637–45.

CAS  PubMed  Article  Google Scholar 

Mason WS, Gill US, Litwin S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology. 2016;151:986–98.

CAS  PubMed  Article  Google Scholar 

Milich DR. The concept of immune tolerance in chronic hepatitis B virus infection is alive and well. Gastroenterology. 2016;151:801–4.

PubMed  Article  Google Scholar 

Liaw YF, Chu CM. Immune tolerance phase of chronic hepatitis B. Gastroenterology. 2017;152:1245–6.

PubMed  Article  Google Scholar 

Schwartz RH. Historical overview of immunological tolerance. Cold Spring Harb Perspect Biol. 2012;4: a006908.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Jeng WJ, Lok AS. Should treatment indications for chronic hepatitis B be expanded? Clin Gastroenterol Hepatol. 2021;10:2006–14.

Article  CAS  Google Scholar 

Lee HW, Chan HL. Unresolved issues of immune tolerance in chronic hepatitis B. J Gastroenterol. 2020;55:383–9.

PubMed  PubMed Central  Article  Google Scholar 

Lok AS, Perrillo R, Lalama CM, et al. Low incidence of adverse outcomes in adults with chronic hepatitis B virus infection in the era of antiviral therapy. Hepatology. 2021;73:2124–40.

CAS  PubMed  Article  Google Scholar 

Mason WS, Jilbert AR, Litwin S. Hepatitis B virus DNA integration and clonal expansion of hepatocytes in the chronically infected liver. Viruses. 2021;13:210.

CAS  PubMed  PubMed Central  Article  Google Scholar 

World Health Organization; Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015. https://www.who.int/publications/i/item/9789241549059. Accessed 01 Dec 2021.

Gane EJ, Charlton MR, Mohamed R, et al. Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resource-limited settings. J Viral Hepat. 2020;27:466–75.

PubMed  Article  Google Scholar 

Wu JF, Su YR, Chen CH, et al. Predictive effect of serial serum alanine aminotransferase levels on spontaneous HBeAg seroconversion in chronic genotype B and C HBV-infected children. J Pediatr Gastroenterol Nutr. 2012;54:97–100.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829–34.

CAS  PubMed  Article  Google Scholar 

Lee HA, Lee HW, Kim IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther. 2020;52:196–204.

CAS  PubMed  Article  Google Scholar 

Lee HW, Chon YE, Kim BK, et al. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. Eur J Intern Med. 2021;84:68–73.

CAS  PubMed  Article  Google Scholar 

Kim GA, Lim YS, Han S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67:945–52.

CAS  PubMed  Article  Google Scholar 

Chu CM, Liaw YF. Prognosis of immune-tolerant-phase chronic hepatitis B. Gut. 2018;67:988.

CAS  PubMed  Article  Google Scholar 

Choi GH, Kim GA, Choi J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther. 2019;50:215–26.

CAS  PubMed  Article  Google Scholar 

Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology. 2013;57:441–50.

CAS  PubMed  Article  Google Scholar 

Oliveri F, Surace L, Cavallone D, et al. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: benign course towards HBsAg clearance. Liver Int. 2017;37:1622–31.

CAS  PubMed  Article  Google Scholar 

Bonacci M, Lens S, Mariño Z, et al. Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone. Aliment Pharmacol Ther. 2018;47:1397–408.

CAS  PubMed  Article